Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2015

Open Access 01-12-2015 | Research article

The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review

Authors: Adam Gater, Mathieu Uhart, Rachael McCool, Emmanuelle Préaud

Published in: BMC Public Health | Issue 1/2015

Login to get access

Abstract

Background

Herpes zoster (HZ) or “shingles” is common in persons aged 50 years or over. HZ is characterised by a painful dermatological rash which typically resolves in approximately one month. Persistent pain for months or years after rash onset, however, is a common complication of HZ; referred to as post-herpetic neuralgia (PHN). Both HZ and PHN have a significant impact on patients’ lives, with considerable implications for healthcare systems and wider society. The aim of the present review is to provide comprehensive documentation and critical appraisal of published data concerning the humanistic, economic and societal burden of HZ in Europe.

Methods

Systematic literature searches were conducted in Medline, EMBASE, PsycINFO, EconLit, HEED and CRD databases. Searches were conducted in July 2014 and restricted to articles published in the past 20 years. Articles were selected for full review by two independent researchers in accordance with predefined eligibility criteria.

Results

From a review of 1619 abstracts, 53 eligible articles, were identified which reported data concerning healthcare resource use (n = 38), direct costs (n = 20), indirect costs (n = 16), total costs (n = 10) and impact on health-related quality of life (HRQoL) (n = 21). Findings highlight that PHN is associated with greater impairments in HRQoL and higher costs of management than HZ. For both HZ and PHN, pain severity is a significant predictor of impact on individuals, healthcare systems and society. While the incidence of HZ and PHN increase with age, age does not appear to be a key driver of overall costs for HZ and PHN. Specifically, while direct costs (e.g. GP, specialists, medications, hospitalisations) tend to be higher for older patients, indirect costs (e.g. work time missed) are higher for younger patients.

Conclusions

Available evidence highlights that HZ and PHN result in significant humanistic and economic burden for patients, healthcare systems and wider societies. A tendency to focus upon healthcare resource use and the direct costs of management at the expense of other impacts (e.g. informal caregivers and formal social care) may result in an underestimation of the true burden of HZ and PHN.
Literature
1.
Opstelten W, Eekhof J, Neven AK, Verheij T. Treatment of herpes zoster. Can Fam Phys Med Fam Can. 2008;54(3):373–7.
2.
Sengupta N, Booy R, Schmitt HJ, Peltola H, Van-Damme P, Schumacher RF, et al. Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr. 2008;167(1):47–55.PubMed
3.
Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13(1):1–10.
4.
Schmader K, Gnann Jr JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197 Suppl 2:S207–15.PubMed
5.
Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract. 1995;45(390):39–45.PubMedPubMedCentral
6.
Dworkin R, Schmander K. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. 2nd ed. Amsterdam: Elsevier; 2001.
7.
Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine. 2006;24(9):1308–14.PubMed
8.
Johnson RW, Rice AS. Pain following herpes zoster: the influence of changing population characteristics and medical developments. Pain. 2007;128(1–2):3–5.PubMed
9.
Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7(11):1581–95.PubMed
10.
11.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.PubMed
12.
Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321(7264):794–6.PubMedPubMedCentral
13.
Kost RG, Straus SE. Postherpetic neuralgia–pathogenesis, treatment, and prevention. N Engl J Med. 1996;335(1):32–42.PubMed
14.
Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: Findings from the zoster quality of life (ZQOL) study. Health Qual Life Outcomes. 2014;12(1):92.PubMedPubMedCentral
15.
Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain. 2012;153(2):342–9.PubMed
16.
Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157(11):1217–24.PubMed
17.
Coen PG, Scott F, Leedham-Green M, Nia T, Jamil A, Johnson RW, et al. Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice? Eur J Pain. 2006;10(8):695–700.PubMed
18.
Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19(5):471–5.PubMed
19.
Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain. 2007;132 Suppl 1:S52–9.PubMed
20.
Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23(6):490–6.PubMed
21.
Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplege A, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis: Offic Publ Infect Dis Soc Am. 2001;33(1):62–9.
22.
Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ: Can Med Assoc J = J Assoc Med Can. 2010;182(16):1731–6.
23.
Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis: Offic Publ Infect Dis Soc Am. 2004;39(3):342–8.
24.
Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356–63.PubMed
25.
van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing. 2006;35(2):132–7.PubMed
26.
Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.PubMed
27.
Cebrián-Cuenca A, Díez-Domingo J, San-Martín-Rodríguez M, Puig-Barberá J, Navarro-Pérez J. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian Community of Spain. BMC Infect Dis. 2011;11(1):302.PubMedPubMedCentral
28.
Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47.PubMed
29.
Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230.PubMedPubMedCentral
30.
Mick G, Gallais JL, Simon F, Pinchinat S, Bloch K, Beillat M, et al. [Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over]. Rev Epidemiol Sante Publique. 2010;58(6):393–401.PubMed
31.
Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ: HEPAC: Health Econ Prev Care. 2012;14(6):1015–26.
32.
Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis: Offic Publ Infect Dis Soc Am. 2007;44(10):1280–8.
33.
Schmader KE, Levin MJ, Gnann Jr JW, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.PubMedPubMedCentral
34.
35.
Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration. 2011.
36.
Eurostat. Harmonised Index of Consumer Prices. 2014.
37.
Bayas J, Gil R, Llupiá A, Díez C, Conesa A, Ariza C, et al. Hospitalizaciones por herpes zoster y neuralgia postherpética en Cataluña, 1998–2003. Vacunas. 2011;12(4):122–8.
38.
Berrut G, Baptiste C. Ophthalmic herpes zoster, a complication with a poor prognosis, is now a vaccine-preventable disease. Eur Geriatr Med. 2013;4:S116.
39.
Blein C, Gavazzi G, Paccalin M, Baptiste C, Vainchtock A. Evaluation of the herpes zoster impact as comorbidity factor in 5 pathologies French hospital care among adults aged 50 and older. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2013;16(7):A503.
40.
Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096–109.PubMed
41.
Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(3):393–406.
42.
Bricout H, Perinetti E, Marchettini P, Ragni P, Zotti C, Gabutti G, et al. Description of herpes zoster patients aged over 50 years in Italy-A GP based multi center prospective observational study. Eur Geriatr Med. 2013;4:S116–7.
43.
Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003;88(10):862–9.PubMedPubMedCentral
44.
Castro-Lopes JM, Menezes J, Mendonca L, Costa-Pereira A, Azevedo L. The impact of post-herpetic neuralgia: a prospective multicentre study on pain and health related quality of life. Eur Geriatr Med. 2013;4:S79.
45.
de Juanes J, Arrazola P, García de Codes A, Ariza C, Gil R, San Martín M, et al. Hospitalizaciones por herpes zoster y neuralgia postherpética en la Comunidad de Madrid, 1998–2003. Vacunas. 2011;12(4):129–35.
46.
Di Legami V, Gianino MM, Ciofi degli Atti M, Massari M, Migliardi A, Tomba GS, et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007;25(43):7598–604.PubMed
47.
Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23–24):3076–90.PubMed
48.
Franco E, Perinetti E, Marchettini P, Ragni P, Zotti C, Gabutti G, et al. Proportion of post herpetic neuralgia among patients with herpes zoster in Italy-A multicenter prospective observational study. Eur Geriatr Med. 2013;4:S115–6.
49.
García-Doval I, Pérez-Zafrilla B, Descalzo MÁ, Roselló R, Hernández MV, Gómez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69(10):1751–5.PubMed
50.
Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis. 2014;14(1):402.PubMedPubMedCentral
51.
Gil A, San-Martin M, Carrasco P, Gonzalez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004;22(29–30):3947–51.PubMed
52.
Gil A, Gil R, Alvaro A, San Martin M, Gonzalez A. Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998–2004). BMC Infect Dis. 2009;9:55.PubMedPubMedCentral
53.
Gil-Prieto R, San-Martín M, Álvaro-Meca A, González-López A, Gil de Miguel A. Herpes zoster hospitalizations of patients with chronic illnesses in Spain, 1998–2004. Vacunas. 2011;12(3):95–101.
54.
Gil-Prieto R, Walter S, Gonzalez-Escalada A, Garcia-Garcia L, Marin-Garcia P, Gil-de-Miguel A. Different vaccination strategies in spain and its impact on severe varicella and zoster. Vaccine. 2014;32(2):277–83.PubMed
55.
Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al. Herpes zoster: Burden of disease in France. Vaccine. 2010;28(50):7933–8.PubMed
56.
Lionis CD, Vardavas CI, Symvoulakis EK, Papadakaki MG, Anastasiou FS, Antonopoulou MD, et al. Measuring the burden of herpes zoster and post herpetic neuralgia within primary care in rural Crete, Greece. BMC Fam Pract. 2011;12(1):136.PubMedPubMedCentral
57.
Loncar Z, Mestrovic AH, Bilic M, Taksic I, Mickovic V. Quality of pain in herpes zoster patients Kvaliteta boli kod pacijenata oboljelih od herpes zostera. Coll Antropol. 2013;37(2):527–30.PubMed
58.
Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Zeitschr Gesundheitswissenschaften = J Public Health. 2012;20(4):441–51.
59.
Mesquita M, Froes F. Hospital admissions for Herpes Zoster in Portugal between 2000 and 2010 Internamentos hospitalares por Herpes Zoster em Portugal entre 2000 e 2010. Acta Med Port. 2013;26(5):531–6.PubMed
60.
Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Effect Resour Allocation: C/E. 2010;8:7.PubMedCentral
61.
Morant-Talamante N, Diez-Domingo J, Martinez-Ubeda S, Puig-Barbera J, Aleman-Sanchez S, Perez-Breva L. Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infect Dis. 2013;13(1):463.PubMedPubMedCentral
62.
Mordarski S, Lysenko L, Gerber H, Zietek M, Gredes T, Dominiak M. The effect of treatment with fentanyl patches on pain relief and improvement in overall daily functioning in patients with postherpetic neuralgia. J Physiol Pharmacol. 2009;60 suppl 8:31–5.PubMed
63.
Nilsson J, Cassel T, Lindquist L. Burden of herpes zoster and post-herpetic neuralgia in Sweden. Value Health. 2013;16(7):A347.
64.
Pierik JG, Gumbs PD, Fortanier SA, Van Steenwijk PC, Postma MJ. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012;12:110.PubMedPubMedCentral
65.
Rabaud C, Rogeaux O, Launay O, Strady C, Mann C, Chassany O, et al. Early antiviral treatment fails to completely prevent herpes-related pain. Med Mal Infect. 2013;43(11–12):461–6.PubMed
66.
Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin. 2010;26(7):1607–19.PubMed
67.
Schiffner-Rohe J, Köster I, Beillat M, Lilie H, Schubert I. Resource consumption and health care costs of herpes zoster and postherpetic neuralgia in Germany. Gesundheitsökonomie Qualitätsmanagement. 2011;16(04):216–23.
68.
Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003;70 Suppl 1:S24–30.PubMed
69.
Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J, Perez-Ronco J. [Incidence, resource use and costs associated with postherpetic neuralgia: a population-based retrospective study]. Rev Neurol. 2012;55(8):449–61.PubMed
70.
Souliotis K, Lionis C, Papadakaki M, Papageorgiou M, Tsiaousi I, Bersimis S. The economic burden of herpes zoster on patients visiting primary care settings in Greece-Results from a multicentre study in Crete. Eur Geriatr Med. 2013;4:S117–8.
71.
Studahl M, Petzold M, Cassel T. Disease burden of herpes zoster in Sweden - predominance in the elderly and in women - a register based study. BMC Infect Dis. 2013;13(1):586.PubMedPubMedCentral
72.
Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccine. 2011;7(7):749–56.
73.
Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.PubMedPubMedCentral
74.
van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.PubMed
75.
Volpi A, Gatti A, Serafini G, Costa B, Suligoi B, Pica F, et al. Clinical and psychosocial correlates of acute pain in herpes zoster. J Clin Virol: Offic Publ Pan Am Soc Clin Virol. 2007;38(4):275–9.
76.
Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol. 2008;80(9):1646–52.PubMed
77.
Weinke T, Edte A, Schmitt S, Lukas K. Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey. Zeitschr Gesundheitswissenschaften = J Public Health. 2010;18(4):367–74.
78.
Organization WH. Active ageing: a policy framework. 2002.
79.
Galluzzi KE. Management strategies for herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc. 2007;107(3 Suppl 1):S8–13.PubMed
80.
Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol: Offic Publ Pan Am Soc Clin Virol. 2010;48 Suppl 1:S20–8.
81.
Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes zoster: the European view. Am J Clin Dermatol. 2005;6(5):317–25.PubMed
82.
Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccine. 2008;4(3):238–45.
83.
Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract: Offic J World Inst Pain. 2011;11(4):397–402.
84.
Mortensen GL. Perceptions of herpes zoster and attitudes towards zoster vaccination among 50-65-year-old Danes. Dan Med Bull. 2011;58(12):A4345.PubMed
85.
86.
Yawn BP. Post-shingles neuralgia by any definition is painful, but is it PHN? Mayo Clin Proc Mayo Clin. 2011;86(12):1141–2.PubMed
87.
Singhal PK, Makin C, Pellissier J, Sy L, White R, Saddier P. Work and productivity loss related to herpes zoster. J Med Econ. 2011;14(5):639–45.PubMed
88.
Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12):2047–50.PubMed
Metadata
Title
The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review
Authors
Adam Gater
Mathieu Uhart
Rachael McCool
Emmanuelle Préaud
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2015
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-015-1514-y

Other articles of this Issue 1/2015

BMC Public Health 1/2015 Go to the issue

Research article

Women's position and attitudes towards female genital mutilation in Egypt: A secondary analysis of the Egypt demographic and health surveys, 1995-2014

Study protocol

What is the effect of a combined physical activity and fall prevention intervention enhanced with health coaching and pedometers on older adults’ physical activity levels and mobility-related goals?: Study protocol for a randomised controlled trial

Research article

A systematic review of post-migration acquisition of HIV among migrants from countries with generalised HIV epidemics living in Europe: mplications for effectively managing HIV prevention programmes and policy

Research article

Internal construct validity of the stress-energy questionnaire in a working population, a cohort study

Research article

Pilot to evaluate the feasibility of measuring seasonal influenza vaccine effectiveness using surveillance platforms in Central-America, 2012

Research article

Association between social and built environments and leisure-time physical activity among Chinese older adults - a multilevel analysis